RP drug receives orphan drug designation

Article

Fovea Pharmaceuticals has received designation as Orphan Medicinal Product from the European Commission for rh-RdCVF, its treatment for retinitis pigmentosa (RP).

Fovea Pharmaceuticals has received designation as Orphan Medicinal Product from the European Commission for rh-RdCVF, its treatment for retinitis pigmentosa (RP).

In a study on an animal model of the disease, RdCVF was shown to improve the survival and functionality of retinal cone cells that are responsible for central vision and that are degenerating in patients with RP. The Orphan Drug Designation would entitle Fovea to exclusive marketing rights in European countries for a 10-year period, should it be the first company to receive marketing approval.

Fovea plans to start clinical trials in 2009.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.